Metamizol-Sf

Metamizole sodium, the active ingredient in Metamizol‑Sf, is a pyrazolone presented as a sterile solution for intramuscular and intravenous use. It provides analgesic and antipyretic effects, indicated for the management of moderate to severe pain and for fever reduction in adult patients.

GNH USA supplies Metamizol‑Sf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent product quality, regulatory compliance, and reliable logistics for global healthcare providers.

Metamizole sodium acts as an analgesic and antipyretic within the pyrazolone class, addressing pain and fever pathways. - Acute pain: delivers rapid analgesia for postoperative or trauma‑related pain. - High fever: lowers elevated body temperature when other antipyretics are insufficient. - Colicky abdominal pain: eases spasm‑related discomfort in gastrointestinal conditions.

Metamizole sodium may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: transient light‑headedness after injection. - Injection site pain: local discomfort at the administration site. - Rash: mild skin erythema or itching. - Hypotension: occasional drop in blood pressure.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells, requiring immediate medical attention. - Aplastic anemia: bone‑marrow failure leading to pancytopenia. - Stevens‑Johnson syndrome: severe mucocutaneous reaction. - Anaphylaxis: acute, potentially life‑threatening allergic response. - Hepatic dysfunction: abnormal liver enzyme elevations.

When using Metamizole‑Sf, consider the following safety measures. - Renal impairment: use with caution and monitor renal function. - Hepatic disease: assess liver status before initiation. - History of blood disorders: avoid in patients with prior agranulocytosis or aplastic anemia. - Concomitant myelosuppressive therapy: increase monitoring for bone‑marrow toxicity. - Pregnancy and lactation: prescribe only if potential benefit justifies the risk. - Store at ambient temperature: keep in original container, protect from light and moisture.

Metamizole‑Sf can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Cytotoxic chemotherapy: additive risk of bone‑marrow suppression. - Anticoagulants (e.g., warfarin): potential enhancement of bleeding. - Sulfonamides: increased likelihood of blood dyscrasias.

Moderate Interactions (Monitor Closely): - NSAIDs: possible additive renal toxicity. - ACE inhibitors: may potentiate hypotensive effects. - Diuretics: monitor electrolytes for disturbances.